23.24
-0.3(-1.27%)
Currency In USD
| Previous Close | 23.54 |
| Open | 22.62 |
| Day High | 23.87 |
| Day Low | 21.75 |
| 52-Week High | 23.9 |
| 52-Week Low | 3.42 |
| Volume | 1.84M |
| Average Volume | 1.15M |
| Market Cap | 1.08B |
| PE | -7.59 |
| EPS | -3.06 |
| Moving Average 50 Days | 18.68 |
| Moving Average 200 Days | 13.78 |
| Change | -0.3 |
If you invested $1000 in UroGen Pharma Ltd. (URGN) since IPO date, it would be worth $1,662.37 as of November 08, 2025 at a share price of $23.24. Whereas If you bought $1000 worth of UroGen Pharma Ltd. (URGN) shares 5 years ago, it would be worth $933.71 as of November 08, 2025 at a share price of $23.24.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
UroGen Reports 77.8% Three-Month Complete Response Rate from Phase 3 UTOPIA Trial of UGN-103 and Receives FDA Agreement on NDA Submission Strategy in Recurrent LG-IR-NMIBC Based on UTOPIA Trial
GlobeNewswire Inc.
Nov 06, 2025 12:58 PM GMT
PRINCETON, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced robust preliminary
UroGen Pharma to Present at Guggenheim Securities Healthcare Innovation Conference
GlobeNewswire Inc.
Nov 04, 2025 1:00 PM GMT
PRINCETON, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will prese
UroGen Pharma to Report Third Quarter 2025 Financial Results on Thursday, November 6th, 2025
GlobeNewswire Inc.
Oct 30, 2025 12:00 PM GMT
Conference Call and Webcast Scheduled for Thursday, November 6th, 2025, at 10:00 AM ETPRINCETON, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative sol